From Reuters, May 5:
Bristol Myers Squibb (BMY.N), said on Monday it will invest $40 billion in the U.S. over the next five years, as it seeks to expand its research and manufacturing presence in the country amid U.S. President Donald Trump's tariff threats.
The announcement of new investment was first made by CEO Christopher Boerner in an opinion piece published in Stat News on Monday, and was later confirmed to Reuters by a company spokesperson.
In the Op-Ed, Boerner said the money will be spread across research and development, technology and domestic manufacturing, as U.S. drugmakers prepare to deal with Trump's tariffs....
So far in this series:
Another One: "Amgen to expand Ohio biotech manufacturing plant"
The one that really stood out for us was "Swiss pharmaceuticals company Roche announces $50B investment in US over next 5 years" because it followed so closely on the warning from the EFPIA (also because of the 50 large, that's a lot of money, no matter who you are):
...April 13's "Pharma CEOs alert President von der Leyen to risk of exodus to the US" on The European Federation of Pharmaceutical Industries and Associations:
Here's who "These folks" are ...
